Drug safety under the microscope: Real-World tracking for chronic skin and joint diseases
NCT ID NCT07243782
Summary
This study is monitoring the safety and real-world effectiveness of an already-approved drug called Cosentyx (secukinumab) in Korean patients. It will follow 76 people with moderate-to-severe hidradenitis suppurativa (a painful skin condition), pediatric plaque psoriasis, or juvenile idiopathic arthritis who are prescribed the drug as part of their normal care. The main goal is to track any side effects and see how well the drug works for controlling these chronic conditions in everyday practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 06973, South Korea
Conditions
Explore the condition pages connected to this study.